CXCR4 and leukemia: CXCR4 inhibitors, such as plerixafor, BL-8040, and LY2510924, could disrupt the chemotaxis mediated by the CXCL12/CXCR4 axis and dislodge the leukemic cells from their protective BM niches to increase the sensitivity of leukemia cells to chemotherapy [89–91].